Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth.

Cell communication and signaling : CCS - 1 Aug 2023

Sheng Zenghua, Cao Xu, Deng Ya-Nan, Zhao Xinyu, Liang Shufang

Abstract excerpt

BACKGROUND: The Annexin A6 (AnxA6) protein is known to inhibit the epidermal growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK)1/2 signaling upon EGF stimulation. While the biochemical mechanism of AnxA6 inactivating phosphorylation of EGFR and ERK1/2 is not completely explored in cancer cells. METHODS: Cells were transiently co-transfected with pFlag-AnxA6, pHA-UBC9 and pHis-SUMO1 plasmids...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Liquid
Share to Epidermal Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-1

Share to Mice, Nude

Share to Protein Kinase C-alpha

Share to Sumoylation

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 37528485
DOI: 10.1186/s12964-023-01217-x
PMCID: PMC10391975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth.PMID 37528485Read ↗

Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers.Semantic proximity Read ↗

Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma.Semantic proximity Read ↗

The post-translational modification, SUMOylation, and cancer (Review)Semantic proximity Read ↗

Annexin A11(ANXA 11) facilitates oral squamous cell carcinoma progression via activating the PI3K/AKT signaling pathwaySemantic proximity Read ↗

Annexin A2: Its Molecular Regulation and Cellular Expression in Cancer DevelopmentSemantic proximity Read ↗

Therapeutic Potential of Targeting the SUMO Pathway in CancerSemantic proximity Read ↗

ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal CarcinomaSemantic proximity Read ↗

ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathwaySemantic proximity Read ↗

Sodium butyrate‐activated TRAF6‐TXNIP pathway affects A549 cells proliferation and migrationSemantic proximity Read ↗

PAX6, modified by SUMOylation, plays a protective role in corneal endothelial injurySemantic proximity Read ↗

Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1Semantic proximity Read ↗

Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.